fda tirzepatide news FDA's decision creates uncertainty for patients—and leads to a lawsuit 🛑BREAKING NEWS🛑 THE FDA OFFICIALLY

If you experience significant nausea, switching to lower intensity activities may help

TGA complaints add to research suggesting the GLP-1 receptor agonists may be associated with ophthalmic complications

We prioritize human-centered design, creating interfaces that enhance usability and improve customer satisfaction

In the ELIXA CVOT, lixisenatide was found to be non-inferior to standard of care plus placebo in terms of risk of the composite endpoint (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina)13.4% in the lixisenatide group and 13.2% in the placebo group (hazard ratio, 1.02

It is a prescription medication, widely stocked at pharmacies, and prescribable today by any qualified provider